Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Detalles Bibliográficos
Autores principales: Nakai, Hidekatsu, Matsumura, Noriomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061489/
https://www.ncbi.nlm.nih.gov/pubmed/37007537
http://dx.doi.org/10.21037/atm-22-6389
_version_ 1785017304265785344
author Nakai, Hidekatsu
Matsumura, Noriomi
author_facet Nakai, Hidekatsu
Matsumura, Noriomi
author_sort Nakai, Hidekatsu
collection PubMed
description
format Online
Article
Text
id pubmed-10061489
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-100614892023-03-31 Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer Nakai, Hidekatsu Matsumura, Noriomi Ann Transl Med Editorial Commentary AME Publishing Company 2023-01-29 2023-03-15 /pmc/articles/PMC10061489/ /pubmed/37007537 http://dx.doi.org/10.21037/atm-22-6389 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Nakai, Hidekatsu
Matsumura, Noriomi
Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
title Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
title_full Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
title_fullStr Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
title_full_unstemmed Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
title_short Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
title_sort progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061489/
https://www.ncbi.nlm.nih.gov/pubmed/37007537
http://dx.doi.org/10.21037/atm-22-6389
work_keys_str_mv AT nakaihidekatsu progressionafterdiscontinuationofbevacizumabinthefirstlinetreatmentofovariancancer
AT matsumuranoriomi progressionafterdiscontinuationofbevacizumabinthefirstlinetreatmentofovariancancer

Ejemplares similares